Involvement of the renal kallikrein-kinin system in K(+)-induced diuresis and natriuresis in anesthetized rats

Eur J Pharmacol. 2000 Jul 7;399(2-3):223-7. doi: 10.1016/s0014-2999(00)00382-4.

Abstract

Intravenous infusion of a high-K(+) solution (67.5 mM KCl, 67.5 mM NaCl) to anesthetized rats increased urine volume by 47.6% after 60 min, compared with infusion of a Na(+) solution (135 mM NaCl). This treatment also increased urinary excretion of Na(+) by 32.2%, in parallel with an increase in excretion of K(+) or Cl(-). Urinary excretion of kallikrein increased within 60 min after the start of K(+) infusion. A bradykinin B(2) receptor antagonist, 8-[3-[N-[(E)-3-(6-acetamidopyridin-3-yl)acryloylglycyl]-N-me thylamino ]-2,6-dichlorobenzyloxy]-2-methylquinoline (FR173657; 1.0 mg/kg, i.v. ), inhibited the K(+)-induced diuresis and natriuresis by 41.0% and 26.7%, respectively. These results indicate that K(+) load induces diuresis and natriuresis through the renal kallikrein-kinin system in rats.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anesthesia
  • Animals
  • Chlorides / urine
  • Diuresis / drug effects*
  • Infusions, Intravenous
  • Kallikrein-Kinin System / drug effects*
  • Kallikreins / urine
  • Kidney / drug effects*
  • Kidney / physiology
  • Male
  • Natriuresis / drug effects*
  • Potassium / pharmacology*
  • Potassium / urine
  • Quinolines / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Sodium / pharmacology
  • Sodium / urine
  • Time Factors
  • Urination / drug effects

Substances

  • Chlorides
  • FR 173657
  • Quinolines
  • Sodium
  • Kallikreins
  • Potassium